Assignee
AUTOLUS LTD
GB·53 granted patents·75 pending applications·87 citations·filing 2015–2025
Top patents by PatentIndex Score
128 records- 0196US11034750B2Chimeric antigen receptor (CAR) comprising a CD19-binding domainAUTOLUS LTD·Filed 2018·Granted Jun 15, 2021·8 cites·7 claims
- 0295US12187769B2CellAUTOLUS LTD·Filed 2023·Granted Jan 7, 2025·2 cites·5 claims
- 0395US11091532B2T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptorAUTOLUS LTD·Filed 2015·Granted Aug 17, 2021·8 cites·16 claims
- 0494US11590170B2Chimeric antigen receptorAUTOLUS LTD·Filed 2022·Granted Feb 28, 2023·3 cites·6 claims
- 0594US11434293B2Anti TRBC1 antigen binding domainsAUTOLUS LTD·Filed 2021·Granted Sep 6, 2022·7 cites·10 claims
- 0693US10981970B2Chimeric antigen receptor (CAR) comprising a CD22-binding domainAUTOLUS LTD·Filed 2018·Granted Apr 20, 2021·4 cites·8 claims
- 0793US10800854B2Chimeric cytokine receptors and encoding nucleic acidsAUTOLUS LTD·Filed 2016·Granted Oct 13, 2020·6 cites·22 claims
- 0892US11440961B2Anti TRBC1 antigen binding domainsAUTOLUS LTD·Filed 2018·Granted Sep 13, 2022·7 cites·11 claims
- 0992US10800855B2Chimeric cytokine receptors and encoding nucleic acidsAUTOLUS LTD·Filed 2018·Granted Oct 13, 2020·4 cites·15 claims
- 1090US11058722B2Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domainAUTOLUS LTD·Filed 2016·Granted Jul 13, 2021·4 cites·13 claims
- 1190US10954530B2Retroviral and lentiviral vectorsAUTOLUS LTD·Filed 2016·Granted Mar 23, 2021·5 cites·12 claims
- 1289US11851672B2CAR T-cells comprising transcriptional circuitsAUTOLUS LTD·Filed 2018·Granted Dec 26, 2023·3 cites·2 claims
- 1389US11365262B2CellAUTOLUS LTD·Filed 2016·Granted Jun 21, 2022·4 cites·19 claims
- 1489US2025353893A1CellAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 1587US12049510B2Chimeric antigen receptorAUTOLUS LTD·Filed 2019·Granted Jul 30, 2024·2 cites·14 claims
- 1687US11180553B2Chimeric antigen receptorAUTOLUS LTD·Filed 2017·Granted Nov 23, 2021·4 cites·12 claims
- 1786US12398194B2Cell lexpressing two chimeric antigen receptors (CARs) at the cell surfaceAUTOLUS LTD·Filed 2023·Granted Aug 26, 2025·0 cites·20 claims
- 1886US11479613B2Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteinsAUTOLUS LTD·Filed 2020·Granted Oct 25, 2022·1 cites·11 claims
- 1986US2024033292A1CellAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 2085US11103532B2Chimeric proteinAUTOLUS LTD·Filed 2019·Granted Aug 31, 2021·2 cites·21 claims
- 2184US2024033289A1CellAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 2283US12234295B2Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereofAUTOLUS LTD·Filed 2022·Granted Feb 25, 2025·0 cites·22 claims
- 2383US11701386B2CellAUTOLUS LTD·Filed 2018·Granted Jul 18, 2023·1 cites·7 claims
- 2482US11959084B2Nucleic acid constructAUTOLUS LTD·Filed 2019·Granted Apr 16, 2024·1 cites·21 claims
- 2582US2025368715A1Chimeric Antigen ReceptorAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 2681US11982673B2MethodsAUTOLUS LTD·Filed 2022·Granted May 14, 2024·0 cites·10 claims
- 2781US11982672B2MethodsAUTOLUS LTD·Filed 2022·Granted May 14, 2024·0 cites·8 claims
- 2881US11885806B2Method for depleting malignant T-cellsAUTOLUS LTD·Filed 2022·Granted Jan 30, 2024·0 cites·10 claims
- 2981US11885807B2Method for depleting malignant T-cellsAUTOLUS LTD·Filed 2022·Granted Jan 30, 2024·0 cites·8 claims
- 3081US2025388929A1Retroviral and Lentiviral VectorsAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 3181US2023194535A1MethodsAUTOLUS LTD·Filed 2022·Application pending·0 cites
- 3281US2025197464A1CellAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 3380US11578126B2Chimeric antigen receptor (CAR) comprising a CD19-binding domainAUTOLUS LTD·Filed 2019·Granted Feb 14, 2023·1 cites·21 claims
- 3480US10919951B2Chimeric antigen receptorAUTOLUS LTD·Filed 2018·Granted Feb 16, 2021·2 cites·7 claims
- 3580US2025277047A1Chimeric antigen receptorAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 3679US11466070B2Signalling systemAUTOLUS LTD·Filed 2017·Granted Oct 11, 2022·2 cites·12 claims
- 3779US2024301088A1Chimeric antigen receptorAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 3878US12454578B2Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptorsAUTOLUS LTD·Filed 2022·Granted Oct 28, 2025·0 cites·4 claims
- 3978US11385233B2Methods of depleting malignant T-cellsAUTOLUS LTD·Filed 2018·Granted Jul 12, 2022·1 cites·9 claims
- 4078US11345734B2Chimeric T cellAUTOLUS LTD·Filed 2016·Granted May 31, 2022·1 cites·5 claims
- 4178US11242377B2Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomainsAUTOLUS LTD·Filed 2016·Granted Feb 8, 2022·1 cites·35 claims
- 4278US2024076352A1Chimeric Antigen ReceptorAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 4378US2025314655A1MethodsAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 4478US2025019434A1Chimeric antigen receptorAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 4578US2023346838A1Chimeric Antigen ReceptorAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 4678US2024384278A1Nucleic acid constructAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 4777US2025333505A1T-cell receptor constant region 1 antibody or t-cell receptor constant region 2 antibodyAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 4877US2025333538A1Chimeric cytokine receptorAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 4977US2026062458A1Chimeric antigen receptorAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 5076US12516119B2Anti TRBC1 antigen binding domainsAUTOLUS LTD·Filed 2022·Granted Jan 6, 2026·0 cites·6 claims
Showing the top 50 of 128 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →